Advertisement
Document › Details
Apceth Biopharma GmbH. (5/31/17). "Press Release: Apceth Biopharma Appoints Dusan Kosijer as Chief Financial Officer". Munich.
Organisation | Apceth Biopharma GmbH | |
Group | Resonac (Group) | |
Organisation 2 | Accovion GmbH | |
Group | Clinipace (Group) | |
Product | contract manufacturing (biologicals) | |
Product 2 | gene therapy | |
Person | Kosijer, Dusan (Apceth 201705– CFO of Apceth Biopharma GmbH joined 10/16 before Accovion GmbH) | |
Person 2 | Günther, Christine Elfriede (Apceth 201108 Managing Director STEPPED DOWN 2/21) | |
apceth Biopharma GmbH, a cell therapy company with a proprietary portfolio of genetically modified mesenchymal stem cell therapeutics for the treatment of inflammatory diseases and cancer, and a successful Contract Development and Manufacturing Organisation (CDMO) for cell and gene therapy products, announced today the appointment of Mr Dusan Kosijer as new Chief Financial Officer, effective immediately.
Mr Kosijer has joined apceth's team already in October 2016, taking over the responsibility for the company's finance strategy and operations, and also the leadership of apceth's accountant and purchasing team. Mr Kosijer is Certified Management Accountant by training and brings with him 14 years of outstanding experience at leading positions in corporate finance and pharmaceutical contract service business. He joined apceth from his previous position as CFO at Accovion GmbH, one of the leading independent European Clinical Research Organisations.
In his new role as a member of the senior management, Mr Kosijer's key impact on apceth's effective business and executive strategy will intensify further.
"I am very pleased to welcome Dusan to apceth's executive management team. With his longstanding background as a finance executive in the pharmaceutical contract services sector, he will play a major role in further strengthening our successful track record as one of the leading CDMOs for complex cell and gene therapy products," said Dr Christine Guenther, apceth's CEO, and added: "Moreover, Dusan's experience will strongly promote our dynamic innovative strategy behind apceth's unique proprietary pipeline of genetically modified stem cell therapies."
"I am excited and honoured to be able to contribute to the company that operates successfully for almost 10 years in the fast-moving field of cell and gene therapy,” said Mr Kosijer. “We will continue to be relentless in our efforts to be the best and the most reliable CDMO partner for the growing number of our renowned international clients. In parallel, apceth's pipeline has recently entered a very thrilling phase, encouraging us to accelerate further the development of our first-in-class, first-in-man cell-based gene therapies."
About apceth Biopharma GmbH
apceth Biopharma is a pioneering biopharmaceutical company with a pipeline of cell-based gene therapeutics for the treatment of major chronic diseases (chronic lung disease, metabolic and autoimmune diseases) and solid cancer. The company's proprietary platform technology is based on state-of-the-art genetic engineering of mesenchymal stem cells. apceth Biopharma is also a successful Contract Development and Manufacturing Organization for complex cell and gene therapy products with a high international reputation. Based in Munich (Germany) in the heart of Europe, apceth Biopharma provides its proven expertise and state-of-the-art GMP facilities to the clients from around the world. apceth Biopharma was founded as apceth GmbH & Co. KG in 2007. The company is privately owned by its founders and private investors (Santo Holding GmbH and FCP Biotech Holding GmbH).
Contact
apceth Biopharma GmbH
Dr Christine Guenther, CEO
Max-Lebsche-Platz 30
81377 Munich
Germany
+49 (0)89 7009608 0
contact@apceth.com
www.apceth.com
Record changed: 2023-06-05 |
Advertisement
More documents for Resonac (Group)
- [1] Lift BioSciences Ltd.. (2/16/23). "Press Release: LIfT BioSciences and Minaris Regenerative Medicine Enter into a Manufacturing Partnership". London & Munich....
- [2] Minaris Regnerative Medicine GmbH. (2/22/21). "Press Release: MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership for MVX-ONCO-2 Cancer Immunotherapy". Geneva & Munich....
- [3] Minaris Regnerative Medicine GmbH. (1/25/21). "Press Release: Dusan Kosijer Apppointed CEO of Minaris Regenerative Medicine GmbH". Munich....
- [4] Minaris Regnerative Medicine GmbH. (9/23/20). "Press Release: Hitachi Chemical’s Global Regenerative Medicine Business Renamed Minaris Regenerative Medicine". Allendale, NJ, Munich & Yokohama....
- [5] Ori Biotech Ltd.. (7/28/20). "Press Release: Ori Biotech Appoints Thomas Heathman, PhD to Lead Commercial Operations in North America". Philadeliphia, PA & London....
- [6] Apceth Biopharma GmbH. (5/11/20). "Press Release: Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with bluebird bio". Allendale, NJ & Munich....
- [7] Bluebird Bio, Inc.. (10/22/19). "Press Release: European Medicines Agency Approves Refined Commercial Manufacturing Specifications for Zynteglo". Cambridge, MA....
- [8] Hitachi Chemical Co., Ltd.. (1/31/19). "Press Release: Notice Regarding the Stock Acquisition of Apceth Biopharma GmbH, a Contract Manufacturer of Regenerative Medicine Products"....
- [9] Apceth Biopharma GmbH. (1/31/19). "Press Release: Hitachi Chemical Co. Ltd. to Acquire Apceth Biopharma GmbH". Munich....
- [10] Apceth Biopharma GmbH. (11/16/18). "Press Release: Apceth Biopharma GmbH Manufactures DCprime’s Cell-based Cancer Vaccine for Phase II Clinical Study". Munich....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top